| Name | Title | Contact Details |
|---|
Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.